20 September 2017 | News
Russia and India to beef-up their technologies for the treatment of HIV infection The second BIOTECHMED biotechnology conference took place in Gelendzhik, September 14-15, 2017.
The National Immunobiological Company (Nacimbio), part of Rostec state corporation, at Biotechmed conference signed an agreement on the transfer of technology for the production of ready-made dosage forms and active pharmaceutical substances with the Indian pharmaceutical company Mylan Laboratories Limited, part of a global company Mylan NV (USA). Within the framework of the license agreement, there will be a transfer of technology for the production of both ready-made forms and active pharmaceutical substances for the creation of modern combined drugs for the treatment of HIV infection.
At “Biotechmed-2017” conference Rostec CEO Sergei Chemezov said that the Corporation's activities are aimed at reducing dependence on imported medicines. At the same time, the corporation is ready for a technological partnership in the pharmaceutical industry. "We are developing our own drug production, jointly with well-known foreign pharmaceutical companies, who are ready to localize production of their products in Russia," said Sergei Chemezov.
At “Biotechmed-2017” conference, Nacimbio holding company (part of Rostec State Corporation) signed an agreement on technology transfer with the Indian company Mylan Laboratories Ltd.
“We are starting cooperation with India's Mylan Laboratories Ltd. This will provide us with the supply of substances, transfer of technology and the creation of modern combination drugs for HIV treatment. As a result, their cost in the Russian market will significantly decrease,” said Sergey Chemezov.
The head of the corporation also noted that in the coming years Nacimbio plans to take a leading position in the production of immunobiological drugs. Nacimbio supplies domestic vaccines under state contracts with the Ministry of Health, which are included in the national calendar of preventive vaccinations. In total, 17 items of vaccines are supplied, of which 14 are completely Russian-made.
The second BIOTECHMED biotechnology conference took place in Gelendzhik, September 14-15, 2017. BIOTECHMED conference was held with the support of the Ministry of Health of the Russian Federation, the Ministry of Industry and Trade of the Russian Federation and the Ministry of Agriculture of the Russian Federation. The strategic partner of the conference was Rostec State Corporation.